Genmab — November 2020

[peter12]

@EL_ I think its still online ? But that was what he said

[Sukkeralf]

It also provided its own 2025 sales estimates for a number of key brands, including established growth drivers – Cosentyx ($5.6 billion), Entresto ($4.9 billion) and Kisqali ($1.6 billion), recent launches – Zolgensma ($2 billion), Kesimpta ($1.8 billion) and Piqray ($1.3 billion) - and the approval pending inclisiran ($1.4 billion).

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[E_L]

yes, i heard that , but i stopped after 1/2 hour, because they did not follow the presentation anymore, too long to sit through everything, i was wondering if they said more later on, on the number of subscriptions

[E_L]

in the presentation it reads : 95%+ (~6000) of MS prescribing targets reached

[E_L]

Solsen thought that means 6,000 prescriptions, I am not so sure, so hoping for clarification

[GeorgeBest]

E L - why not post a question for Fridays q/a

[E_L]

yes, i can try, if nobody here knows. Doubt he'll answer that though

[Solsen]

Well I dont know. More likely its the number of physicians Novartis salesforce are targeting.

[Solsen]

Wonder what 5,2% NBRx is in numbers - New of brand presciptions ?

[Helge_LarsenPI-redaktør]

Hej alle, Er virkelig seriøst bagud på spørgsmål til Q&A fredag. Læg dem endelig ind i aften eller i morgen eller senest fredag formiddag. På forhånd tak.

[Solsen]

Jeg har fri i morgen så jeg skal nok fylde på

[E_L]

if my guestimate for Ocrevus is roughly correct at new patients 5,000 for 10 weeks in the US then i thought it should be at least 260? I am probably doing this completely wrong... 260 patients would bring $26mio in revenue in 1 year

[E_L]

I don't think i have much for QA, most of my questions were answered in the last few weeks.... and Enapotamab Q
yesterday lol

[Helge_LarsenPI-redaktør]

Thanks guys. I can always count on you.

[Helge_LarsenPI-redaktør]

God morgen.

[Plimsoller]

God morgen

[deleted-user]

Q&A - Er der spørgsmål omkring ensretning mellem "aktierne" i Danmark og US 1:10?

[deleted-user]

Q&A - spørgsmål omkring Genmab' kapitalbehov? Balance mellem kapitalbehov til udvikling af pipeline og kurspleje ved dividende
?

[GeorgeBest]

Bare stil dine spørgsmål i Q/A chatten, så kan Helge udelade det hvis der er lignende spørgsmål fra en anden. Kvaliteten af Q/A højnes, hvis Helge har flere Qs at vælge i mellem.